Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Myelin-associated oligodendrocyte basic protein (MOBP) is a small, highly basic, cytoplasmic protein expressed exclusively by oligodendrocytes in the central nervous system after birth. It constitutes one of the most abundant proteins in CNS myelin, is predicted to play a structural role in the compaction or stabilization of the myelin sheath, and may interact with membrane phospholipids. MOBP arises from multiple splice variants, all primarily expressed in oligodendrocytes. Its functional importance is supported by its timing in development and localization to myelinated CNS regions, although knockout studies show that its loss does not lead to overt myelination defects. MOBP contains immunodominant epitopes implicated in animal models of autoimmune encephalomyelitis and may contribute to the pathogenesis of multiple sclerosis[1][2][3][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Myelin-associated oligodendrocyte basic protein (MOBP).